ZYUS LIFE SCIENCES CORP (ZYUS.CA) Stock Fundamental Analysis

TSX-V:ZYUS • CA9899601095

0.64 CAD
-0.02 (-3.03%)
Last: Feb 19, 2026, 07:00 PM
Fundamental Rating

0

ZYUS gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ZYUS have multiple concerns. ZYUS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ZYUS had negative earnings in the past year.
  • ZYUS had a negative operating cash flow in the past year.
  • ZYUS had negative earnings in 4 of the past 5 years.
  • ZYUS had a negative operating cash flow in each of the past 5 years.
ZYUS.CA Yearly Net Income VS EBIT VS OCF VS FCFZYUS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of ZYUS (-311.03%) is worse than 93.94% of its industry peers.
Industry RankSector Rank
ROA -311.03%
ROE N/A
ROIC N/A
ROA(3y)-112.26%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZYUS.CA Yearly ROA, ROE, ROICZYUS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • Looking at the Gross Margin, with a value of 13.12%, ZYUS is doing worse than 72.73% of the companies in the same industry.
  • ZYUS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYUS.CA Yearly Profit, Operating, Gross MarginsZYUS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

0

2. Health

2.1 Basic Checks

  • ZYUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ZYUS has more shares outstanding
  • The number of shares outstanding for ZYUS has been increased compared to 5 years ago.
  • Compared to 1 year ago, ZYUS has a worse debt to assets ratio.
ZYUS.CA Yearly Shares OutstandingZYUS.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZYUS.CA Yearly Total Debt VS Total AssetsZYUS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • ZYUS has an Altman-Z score of -28.07. This is a bad value and indicates that ZYUS is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -28.07, ZYUS is doing worse than 90.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.07
ROIC/WACCN/A
WACC7.92%
ZYUS.CA Yearly LT Debt VS Equity VS FCFZYUS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 0.10 indicates that ZYUS may have some problems paying its short term obligations.
  • With a Current ratio value of 0.10, ZYUS is not doing good in the industry: 93.94% of the companies in the same industry are doing better.
  • ZYUS has a Quick Ratio of 0.10. This is a bad value and indicates that ZYUS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.07, ZYUS is doing worse than 93.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.07
ZYUS.CA Yearly Current Assets VS Current LiabilitesZYUS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.18% over the past year.
  • The Revenue has been growing slightly by 2.88% in the past year.
EPS 1Y (TTM)13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.36%
Revenue 1Y (TTM)2.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-14.63%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.72%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.77%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYUS.CA Yearly Revenue VS EstimatesZYUS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2023 2024 2025 100K 200K 300K 400K 500K
ZYUS.CA Yearly EPS VS EstimatesZYUS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.1 -0.2 -0.3 -0.4

0

4. Valuation

4.1 Price/Earnings Ratio

  • ZYUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYUS.CA Price Earnings VS Forward Price EarningsZYUS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYUS.CA Per share dataZYUS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • ZYUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ZYUS LIFE SCIENCES CORP

TSX-V:ZYUS (2/19/2026, 7:00:00 PM)

0.64

-0.02 (-3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-27
Earnings (Next)N/A
Inst Owners0.17%
Inst Owner ChangeN/A
Ins Owners11%
Ins Owner ChangeN/A
Market Cap49.93M
Revenue(TTM)465.00K
Net Income(TTM)-33.74M
Analysts80
Price Target1.53 (139.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)11.39%
Min Revenue beat(2)3.96%
Max Revenue beat(2)18.81%
Revenue beat(4)3
Avg Revenue beat(4)8.28%
Min Revenue beat(4)-2.54%
Max Revenue beat(4)18.81%
Revenue beat(8)6
Avg Revenue beat(8)7.16%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)42.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 107.37
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.01
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -311.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.12%
FCFM N/A
ROA(3y)-112.26%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.35%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.07
Altman-Z -28.07
F-Score2
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.36%
EPS Next Y52.72%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-14.63%
Revenue Next Year16.77%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.17%
OCF growth 3YN/A
OCF growth 5YN/A

ZYUS LIFE SCIENCES CORP / ZYUS.CA FAQ

What is the fundamental rating for ZYUS stock?

ChartMill assigns a fundamental rating of 0 / 10 to ZYUS.CA.


Can you provide the valuation status for ZYUS LIFE SCIENCES CORP?

ChartMill assigns a valuation rating of 0 / 10 to ZYUS LIFE SCIENCES CORP (ZYUS.CA). This can be considered as Overvalued.


How profitable is ZYUS LIFE SCIENCES CORP (ZYUS.CA) stock?

ZYUS LIFE SCIENCES CORP (ZYUS.CA) has a profitability rating of 0 / 10.


What is the financial health of ZYUS LIFE SCIENCES CORP (ZYUS.CA) stock?

The financial health rating of ZYUS LIFE SCIENCES CORP (ZYUS.CA) is 0 / 10.